Neurosciences News

WAILEA, Hawaii — The Advanced Research Projects Agency for Health has launched a program to restore vision through the transplantation of whole human eyes, according to a speaker here.

WAILEA, Hawaii — In this Healio video perspective, Prem S. Subramanian, MD, PhD, discusses the neuro-ophthalmology program at Hawaiian Eye/Retina 2024.

The Advanced Research Projects Agency for Health has launched the Transplantation of Human Eye Allografts program, which aims to transplant whole human eyes to restore vision, according to a press release.

The top Healio neuroscience-related articles in 2023 included an overview of an accelerated “papilledema protocol” and data on nonarteritic ischemic optic neuropathy risk factors and prevalence in the U.S.

Atsena Therapeutics reported positive 12-month safety and efficacy data from a phase 1/2 trial of ATSN-101 gene therapy in GUCY2D-associated Leber congenital amaurosis.

A novel, eye-tracking metrics device aided in the detection of dementia risk in a small population of Colombian individuals with differing levels of education, according to a poster presented at CTAD.

Treatment with an oral suspension of active gold as an adjunct to disease-modifying therapy was linked to improved neurological function in those with stable relapsing MS, according to a poster presented at ECTRIMS 2023.

Presence of cytokine proteins in those with neuromyelitis optica spectrum disorder was linked to disease activity, which was lessened after treatment with inebilizumab, according to a presentation from ECTRIMS 2023.

PHILADELPHIA — Tracking to chart various eye movements including saccadic and fixation may be effective in differentiating neurological differences between children with ASD and neurotypical children, according to a poster presentation.

The FDA has issued a complete response letter to AstraZeneca for its supplemental biologics license application of Ultomiris to treat adults with neuromyelitis optica spectrum disorder who are anti-aquaporin-4 antibody positive.